APR 14·Stock Titan▲
A 30-mm lung nodule looked cancerous; another scan showed it was not
bioAffinity Technologies (BIAF) released a case study demonstrating how its CyPath® Lung diagnostic test helped a physician defer an unnecessary biopsy for a patient with a suspicious pulmonary nodule. Despite imaging and risk models suggesting a high likelihood of cancer, the noninvasive sputum-based test indicated "Unlikely Malignancy," leading to a follow-up scan that showed the nodule had resolved. This highlights CyPath® Lung's potential to provide objective data for managing indeterminate lung nodules, especially in high-risk patients where invasive procedures carry significant risks.
APR 1·Medical Product Outsourcing▲
bioAffinity Technologies Appoints Three New Medical and Scientific Advisory Board Members
bioAffinity Technologies has expanded its Medical and Scientific Advisory Board with the appointment of three new members: Drs. David Ost, Daniel Sterman, and J. Scott Ferguson. These appointments aim to align the board with the company's clinical, scientific, and commercial priorities, particularly for its noninvasive lung cancer diagnostic test, CyPath Lung. The new members are highly respected leaders in pulmonary medicine and lung cancer care, and their expertise will support the integration and adoption of CyPath Lung for early lung cancer detection.
